Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Hospital Microbiome Surveillance in Qatar

PROVIDER: PRJNA1043714 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR26906500_1.fastq.gz	Fastqsanger.gz
	SRR26906500_2.fastq.gz	Fastqsanger.gz
	SRR26906600_1.fastq.gz	Fastqsanger.gz
	SRR26906600_2.fastq.gz	Fastqsanger.gz
	SRR26906501_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 470

Similar Datasets

Klebsiella pneumoniae

Project description:Klebsiella pneumoniae hospital surveillance

| PRJNA351909 | ENA

Hospital Microbiome

Project description:Hospital Microbiome

| PRJEB31632 | ENA

Project description:Hospital Microbiome Isolates

| PRJNA741123 | ENA

Project description:Oral microbiome of Hypertension subjects from Qatar Biobank

| PRJNA643969 | ENA

Genomic Surveillance

Project description:Isolates obtained from Hospital Genomic Surveillance

| PRJEB83276 | ENA

Identification of medication-microbiome interactions that impact gut infection

Project description:The majority of people in the U.S. manage health through at least one prescription drug. Drugs classified as non-antibiotics can adversely affect the gut microbiome and disrupt intestinal homeostasis. Here, we identified medications associated with an increased risk of GI infections across a population cohort of more than 1 million individuals monitored over 15 years. Notably, the cardiac glycoside digoxin and other drugs identified in this epidemiological study are sufficient to alter microbiome composition and risk of Salmonella enterica subsp. Typhimurium (S. Tm) infection in mice. The impact of digoxin treatment on S. Tm infection is transmissible via the microbiome, and characterization of this interaction highlights a digoxin-responsive b-defensin that alters microbiome composition and consequent immune surveillance of the invading pathogen. Combining epidemiological and experimental approaches thus provides an opportunity to uncover drug-host-microbiome-pathogen interactions that increase infection risk in human populations.

2025-05-12 | GSE274850 | GEO

Changes in intestinal permeability and gut microbiota following diet-induced weight loss in patients with metabolic dysfunction-associated steatohepatitis and liver fibrosis

Project description:We explore whether a low-energy diet intervention for Metabolic dysfunction-associated steatohepatitis (MASH) improves liver disease by means of modulating the gut microbiome. 16 individuals were given a low-energy diet (880 kcal, consisting of bars, soups, and shakes) for 12 weeks, followed by a stepped re-introduction to whole for an additional 12 weeks. Stool samples were obtained at 0, 12, and 24 weeks for microbiome analysis. Fecal microbiome were measured using 16S rRNA gene sequencing. Positive control (Zymo DNA standard D6305) and negative control (PBS extraction) were included in the sequencing. We found that low-energy diet improved MASH disease without lasting alterations to the gut microbiome.

2024-12-31 | E-MTAB-14061 | biostudies-arrayexpress

16S rRNA amplicon sequencing Moving hospital microbiome (MHM)

Project description:Moving hospital microbiome project

| PRJEB92068 | ENA

indoor metagenome

Project description:Hospital environment surface microbiome

| PRJNA301917 | ENA

Project description:Hospital Wastewater Microbiome Analysis

| PRJNA1179688 | ENA